What does Dogwood Therapeutics, Inc. do?
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron,…
What is Dogwood Therapeutics, Inc.'s P/E and P/B ratio?
Dogwood Therapeutics, Inc. has a P/E ratio of 0.5 and a P/B ratio of 0.56.
What is Dogwood Therapeutics, Inc.'s debt-to-equity ratio?
Dogwood Therapeutics, Inc. has a debt-to-equity ratio of 0.00.
How much does Dogwood Therapeutics, Inc. owe compared with what it owns?
Dogwood Therapeutics, Inc. owes $0.15 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Dogwood Therapeutics, Inc.'s Positivity rank?
Dogwood Therapeutics, Inc. is ranked #4 of 6,774 companies globally and #3 of 4,000 in United States on PositoAI, with a Positivity Score of 27,827.
Does Dogwood Therapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Dogwood Therapeutics, Inc..
Where can I read the latest news about Dogwood Therapeutics, Inc.?
Recent headlines about Dogwood Therapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Dogwood Therapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Dogwood Therapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.